First-quarter sales of ChromaDex Corp.'s (OTCBB: CDXC) new
BluScience™ line of dietary supplements exceeded management's expectations.
CDXC sold more than 125,000 units of BluScience in the first three months of 2012, more than 50 percent higher than the Company's initial forecast. While promotions and discounts related to the sale of BluScience impacted the Company's net sales, the growing consumer interest these promotional activities generated should benefit the long-term sell-through rate for the product.
As consumer interest builds, the products' availability continues to expand. Already sold in GNC stores, BluScience became available during the first quarter at Walgreens and Drugstore.com, and also at approximately 4,000 independent drugstores and pharmacies in the U.S.
The active ingredient in BluScience is pTeroPure. Based on an antioxidant compound found in blueberries, pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by Frost & Sullivan. Major nutraceutical companies already use pTeroPure in a number of products. Its potential uses in nutraceuticals, food and beverages, cosmeceuticals, sun care products, and more add up to a $600 million market opportunity for CDXC.
CDXC currently trades under $1 but is poised to go much higher as the Company continues to capitalize on pTeroPure and other novel ingredients. Don't miss your chance to invest at these low prices.
Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit http://www.redchip.com/disclosures.asp?src=rcv.